Get the Stockscreener App
1.77
8.05%
-0.155
After Hours:
1.79
0.02
+1.13%
X 4 Pharmaceuticals Inc stock is traded at $1.77, with a volume of 826.02K.
It is down -8.05% in the last 24 hours and down -6.84% over the past month.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
See More
Previous Close:
$1.925
Open:
$1.9
24h Volume:
826.02K
Relative Volume:
1.09
Market Cap:
$10.25M
Revenue:
-
Net Income/Loss:
$-16.76M
P/E Ratio:
-22.12
EPS:
-0.08
Net Cash Flow:
$-132.97M
1W Performance:
+18.00%
1M Performance:
-6.84%
6M Performance:
-91.09%
1Y Performance:
-92.98%
1-Day Range:
$1.76
$1.95
1-Week Range:
$1.51
$2.25
52-Week Range:
$1.38
$26.83
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
Name
X 4 Pharmaceuticals Inc
Sector
Industry
Phone
857-529-8300
Address
61 NORTH BEACON STREET, BOSTON, MA
Compare XFOR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
1.77 | 13.82M | 0 | -16.76M | -132.97M | -0.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.16 | 120.29B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
554.58 | 60.26B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
339.80 | 43.10B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
598.89 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.94 | 33.09B | 3.81B | -644.79M | -669.77M | -6.24 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Aug-30-23 | Resumed | B. Riley Securities | Buy |
| Dec-22-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-12-22 | Initiated | Piper Sandler | Overweight |
| Dec-23-19 | Initiated | Oppenheimer | Outperform |
| Dec-18-19 | Initiated | ROTH Capital | Buy |
| Dec-09-19 | Upgrade | Citigroup | Neutral → Buy |
| Dec-05-19 | Initiated | B. Riley FBR | Buy |
| Jun-07-19 | Initiated | Stifel | Buy |
| Jun-05-19 | Initiated | Cowen | Outperform |
View All
X 4 Pharmaceuticals Inc Stock (XFOR) Latest News
How to integrate X4 Pharmaceuticals Inc. into portfolio analysis toolsEntry Points For Growing Stocks Identified by Models - metal.it
Strategies to average down on X4 Pharmaceuticals Inc.Sector-Wise Equity Performance Trend Forecast - Newser
Published on: 2025-07-30 02:25:32 - Newser
X4 Pharmaceuticals Inc. stock trend outlook and recovery pathWeekly Stock Market Strategy Summary - Newser
How X4 Pharmaceuticals Inc. stock performs during market volatilityFree Access to Real-Time Trade Insights - Newser
What analysts say about X4 Pharmaceuticals Inc. stock outlookConservative Long Term Growth Plans Under Review - beatles.ru
X4 Pharmaceuticals Inc. stock daily chart insightsChart Scanner for Swing Trade Timing - Newser
Real time breakdown of X4 Pharmaceuticals Inc. stock performanceFree Daily Smart Money Movement Monitor - Newser
What are analysts’ price targets for X4 Pharmaceuticals Inc. in the next 12 monthsBest Dividend Outlook For Consistent Profits - jammulinksnews.com
What institutional investors are buying X4 Pharmaceuticals Inc. stockSuperior returns - jammulinksnews.com
India Inc Q1 Revenue Growth: 4-6% Estimate - Rediff MoneyWiz
How does X4 Pharmaceuticals Inc. compare to its industry peersExplosive earnings growth - jammulinksnews.com
What makes X4 Pharmaceuticals Inc. stock price move sharplyUnlock expert stock analysis and alerts - jammulinksnews.com
What catalysts could drive X4 Pharmaceuticals Inc. stock higher in 2025Unlock expert insights for smarter investing - jammulinksnews.com
What are the latest earnings results for X4 Pharmaceuticals Inc.Build wealth steadily with proven strategies - jammulinksnews.com
Has X4 Pharmaceuticals Inc. Stock Ever Crashed Historical Volatility ReviewFree Stock Tips Group - Newser
Why X4 Pharmaceuticals Inc. stock attracts strong analyst attentionFree Exclusive Access to Stock Gurus - metal.it
Why X4 Pharmaceuticals Inc. stock is on top investor watchlistsFree Capital Allocation Plans - jammulinksnews.com
Layoff Tracker: Flagship Unicorns Tessera, Generate:Biomedicines Downsize - BioSpace
Fierce Biotech Layoff Tracker 2025: Rocket ejects 30% of staffers; Flagship's Tessera and Generate Bio trim teams - Fierce Biotech
X4 Pharmaceuticals Inc. Stock Analysis and ForecastFree Investment Community - Autocar Professional
Is X4 Pharmaceuticals Inc. a good long term investmentHigh-profit trading signals - jammulinksnews.com
What analysts say about X4 Pharmaceuticals Inc. stockSignificant capital appreciation - jammulinksnews.com
What drives X4 Pharmaceuticals Inc. stock priceUnstoppable profit momentum - jammulinksnews.com
Trump tariffs live updates: Prospects for India, EU deals falter as Trump pushes for higher tariffs - Yahoo Finance
Bronze Infra (534731) Hits 52 Week HighTremendous growth potential - Autocar Professional
Amneal Reports Certain Preliminary Second Quarter 2025 Financial Results - The Manila Times
X 4 Pharmaceuticals Inc Stock (XFOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.23%
0.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):